Saeed Mohammad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Saeed Mohammad has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
- Amy G. Feldman
Department of Pediatrics, Pediatric Liver Center, Digestive Health Institute and Section of Pediatric Gastroenterology, Hepatology & Nutrition Children's Hospital Colorado, University of Colorado Anschutz Medical Campus Aurora Colorado USA
6 shared publications Estella M. Alonso
Department of Pediatrics,Feinberg School of Medicine Northwestern University,Chicago,IL
5 shared publications- Emily Rothbaum Perito
Department of Pediatrics, University of California, San Francisco, CA
4 shared publications - Evelyn Kanyu Hsu
Seattle Children’s Hospital, Seattle, WA
4 shared publications - Mercedes Martinez
Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University, New York City, New York, USA
4 shared publications Shikha S. Sundaram
4 shared publications
Latest Publications
- 5 September 2026
- Published by Elsevier in The Journal of Pediatrics
- Vol. 299
Hepatotoxicity in Adeno-Associated Virus Gene Therapy: Clinical Challenges and Strategic Solutions
- 5 September 2026
- Published by Elsevier in The Journal of Pediatrics
- Vol. 299
Hepatotoxicity in Adeno-Associated Virus Gene Therapy: Clinical Challenges and Strategic Solutions
- Open Access
- 16 September 2025
- Published by Elsevier in Pediatric Neurology
- Vol. 173, 76-78
Reversal of Acute Liver Injury Following Delandistrogene Moxeparvovec Gene Therapy Using Sirolimus and Immunoglobulin
- 16 September 2025
- Published by Elsevier in Pediatric Neurology
- Vol. 173, 76-78
Open AccessReversal of Acute Liver Injury Following Delandistrogene Moxeparvovec Gene Therapy Using Sirolimus and Immunoglobulin
- Open Access
- 1 September 2025
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 21, 1383-1393
Transplant Without Borders: Clinical Outcomes and Challenges in Transborder Living Donor Pediatric Liver Transplantation in Jordan
Purpose: To describe the clinical outcomes, complications, and logistical challenges of pediatric living donor liver transplantation (LT) in Jordanian children referred abroad, in the absence of a national transplant program. Patients and Methods: This retrospective study reviewed all pediatric cases referred to the Jordanian Center for Organ Transplantation (JCOT) for LT between 2019 and 2023. Data were collected from JCOT records and follow-up interviews with caregivers. Variables included patient demographics, indications for transplantation, donor-recipient relationships, post-operative complications, survival outcomes, and financial aspects. Results: A total of 31 children were referred for LT, of whom 20 (64.5%) successfully underwent living donor liver transplantation abroad—primarily in Turkey—while 11 (35.5%) remained on the waiting list. Biliary atresia (25%) was the most common indication, followed by Alagille syndrome and progressive familial intrahepatic cholestasis (each 20%). Primary hyperoxaluria, Crigler-Najjar syndrome, and maple syrup urine disease were also observed. Parents were the most frequent donors (70%). The most common complications were bile duct leakage (35%), portal vein thrombosis (20%), and infections (15%). The 5-year post-transplant survival rate was 90%. Among the waiting list group, four children (36.4%) died before receiving a transplant. No children underwent transplantation for pediatric acute liver failure during the study period. The average cost per transplant covered by the Ministry of Health was $61,071, excluding out-of-pocket expenses borne by families. Conclusion: This study highlights the feasibility and challenges of transborder pediatric liver transplantation in Jordan. While clinical outcomes for transplanted children were favorable, significant barriers remain, including delayed referrals, financial strain, and mortality among waitlisted patients. These findings underscore the urgent need to establish a national pediatric liver transplant program to improve timely access and long-term care for children with end-stage liver disease in Jordan. Plain Language Summary: In Jordan, children who need liver transplants do not have access to a transplant center within the country. Instead, they must travel abroad—usually to Turkey—for this life-saving surgery. This study looked at how this process works, what challenges families face, and how children do after their transplants. The researchers reviewed the records of all Jordanian children referred for liver transplantation between 2019 and 2023. They found that 20 children successfully received a transplant abroad, while 11 others were still waiting. The most common reason for needing a liver transplant was a condition called biliary atresia, which blocks bile flow from the liver and can cause liver failure in infants. All transplants were done using living donors, usually a parent. Although most children who received a transplant survived and did well, many faced serious complications after surgery, such as bile leakage or infections. Sadly, four children on the waiting list died before they could get a transplant. Families also faced financial and emotional stress due to the travel, paperwork, and long hospital stays. This study is the first to describe how pediatric liver transplantation works in Jordan under the current system. It shows that while the overseas model can save lives, it also has major challenges. The researchers highlight the urgent need for a national transplant center in Jordan, along with better coordination, earlier referrals, and long-term follow-up care for these children.
- 1 September 2025
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 21, 1383-1393
Open AccessTransplant Without Borders: Clinical Outcomes and Challenges in Transborder Living Donor Pediatric Liver Transplantation in Jordan
Purpose: To describe the clinical outcomes, complications, and logistical challenges of pediatric living donor liver transplantation (LT) in Jordanian children referred abroad, in the absence of a national transplant program. Patients and Methods: This retrospective study reviewed all pediatric cases referred to the Jordanian Center for Organ Transplantation (JCOT) for LT between 2019 and 2023. Data were collected from JCOT records and follow-up interviews with caregivers. Variables included patient demographics, indications for transplantation, donor-recipient relationships, post-operative complications, survival outcomes, and financial aspects. Results: A total of 31 children were referred for LT, of whom 20 (64.5%) successfully underwent living donor liver transplantation abroad—primarily in Turkey—while 11 (35.5%) remained on the waiting list. Biliary atresia (25%) was the most common indication, followed by Alagille syndrome and progressive familial intrahepatic cholestasis (each 20%). Primary hyperoxaluria, Crigler-Najjar syndrome, and maple syrup urine disease were also observed. Parents were the most frequent donors (70%). The most common complications were bile duct leakage (35%), portal vein thrombosis (20%), and infections (15%). The 5-year post-transplant survival rate was 90%. Among the waiting list group, four children (36.4%) died before receiving a transplant. No children underwent transplantation for pediatric acute liver failure during the study period. The average cost per transplant covered by the Ministry of Health was $61,071, excluding out-of-pocket expenses borne by families. Conclusion: This study highlights the feasibility and challenges of transborder pediatric liver transplantation in Jordan. While clinical outcomes for transplanted children were favorable, significant barriers remain, including delayed referrals, financial strain, and mortality among waitlisted patients. These findings underscore the urgent need to establish a national pediatric liver transplant program to improve timely access and long-term care for children with end-stage liver disease in Jordan. Plain Language Summary: In Jordan, children who need liver transplants do not have access to a transplant center within the country. Instead, they must travel abroad—usually to Turkey—for this life-saving surgery. This study looked at how this process works, what challenges families face, and how children do after their transplants. The researchers reviewed the records of all Jordanian children referred for liver transplantation between 2019 and 2023. They found that 20 children successfully received a transplant abroad, while 11 others were still waiting. The most common reason for needing a liver transplant was a condition called biliary atresia, which blocks bile flow from the liver and can cause liver failure in infants. All transplants were done using living donors, usually a parent. Although most children who received a transplant survived and did well, many faced serious complications after surgery, such as bile leakage or infections. Sadly, four children on the waiting list died before they could get a transplant. Families also faced financial and emotional stress due to the travel, paperwork, and long hospital stays. This study is the first to describe how pediatric liver transplantation works in Jordan under the current system. It shows that while the overseas model can save lives, it also has major challenges. The researchers highlight the urgent need for a national transplant center in Jordan, along with better coordination, earlier referrals, and long-term follow-up care for these children.
- 5 July 2025
- Published by Wiley in Pediatric Obesity
- p. e70037
Metabolic Dysfunction‐Associated Steatotic Liver Disease in an Urban Paediatric Cohort With High Socioeconomic Deprivation
Background: Whether higher socioeconomic deprivation indices are associated with more severe paediatric metabolic dysfunction‐associated steatotic liver disease (MASLD), formerly non‐alcoholic fatty liver disease (NAFLD), remains unknown.Objective: We aimed to evaluate differences in MASLD characteristics and social deprivation in a cohort of urban children.Methods: Retrospective study of 277 paediatric patients ≤ 18 years old evaluated between January 2009 and December 2019 with a suspected diagnosis of MASLD who underwent liver biopsy. Patients were classified as having metabolic dysfunction‐associated steatohepatitis (MASH) based on their NAFLD Activity Score (NAS). Fibrosis was determined based on biopsy presence. Social deprivation index (SDI) scores were calculated using patient address.Results: Patients were predominantly Hispanic males with obesity and a median age of 12 years. Median SDI score was 85 (65–93). Median ALT was significantly higher in patients with MASH compared with MASLD (136 vs. 92 IU/L, p < 0.001) or with fibrosis compared with no fibrosis (120 vs. 68 IU/L, p < 0.001). High SDI group patients had a significantly higher median AST (60 vs. 47 IU/L, p = 0.022), NAS score (4 vs. 3, p = 0.026) and rates of bridging fibrosis (24% vs. 10%, p = 0.023) compared with the lower SDI group.Conclusion: Within a cohort of predominantly Hispanic children with MASLD and high socioeconomic disadvantage, there are significant laboratory and histologic differences in patients with higher SDI scores, suggesting increased MASLD severity.
- 5 July 2025
- Published by Wiley in Pediatric Obesity
- p. e70037
Metabolic Dysfunction‐Associated Steatotic Liver Disease in an Urban Paediatric Cohort With High Socioeconomic Deprivation
Background: Whether higher socioeconomic deprivation indices are associated with more severe paediatric metabolic dysfunction‐associated steatotic liver disease (MASLD), formerly non‐alcoholic fatty liver disease (NAFLD), remains unknown.Objective: We aimed to evaluate differences in MASLD characteristics and social deprivation in a cohort of urban children.Methods: Retrospective study of 277 paediatric patients ≤ 18 years old evaluated between January 2009 and December 2019 with a suspected diagnosis of MASLD who underwent liver biopsy. Patients were classified as having metabolic dysfunction‐associated steatohepatitis (MASH) based on their NAFLD Activity Score (NAS). Fibrosis was determined based on biopsy presence. Social deprivation index (SDI) scores were calculated using patient address.Results: Patients were predominantly Hispanic males with obesity and a median age of 12 years. Median SDI score was 85 (65–93). Median ALT was significantly higher in patients with MASH compared with MASLD (136 vs. 92 IU/L, p < 0.001) or with fibrosis compared with no fibrosis (120 vs. 68 IU/L, p < 0.001). High SDI group patients had a significantly higher median AST (60 vs. 47 IU/L, p = 0.022), NAS score (4 vs. 3, p = 0.026) and rates of bridging fibrosis (24% vs. 10%, p = 0.023) compared with the lower SDI group.Conclusion: Within a cohort of predominantly Hispanic children with MASLD and high socioeconomic disadvantage, there are significant laboratory and histologic differences in patients with higher SDI scores, suggesting increased MASLD severity.
- Open Access
- 19 May 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (2) , 177-182
Severe hepatitis in pediatric patients: The Severe Hepatitis In Pediatric Patients (SHIPP) registry
Objectives: Clusters of severe acute hepatitis in children were reported worldwide beginning in October 2021. Although most children recovered, some progressed to liver failure leading to death or liver transplantation. Herein, we characterize the clinical characteristics, and outcomes of this group of children through an international collaborative effort.Methods: Participation was solicited via a global listserv to pediatric gastroenterologists worldwide. Patients 500 U/L, without chronic liver disease or acetaminophen ingestion were eligible. Data were submitted by individual sites into a Research Electronic Data Capture registry created in July 2022.Results: Two hundred and seven cases were collected, with a peak incidence of 28 in April 2022. The median age was 40 months, 52.7% were male, 63.3% were white, and 44% were Hispanic. At presentation, 80% reported gastrointestinal symptoms followed by fever (27.7%). The median duration of hospitalization was 5.5 days with 51 patients requiring intensive care. Adenovirus serum/whole blood DNA was detected in 28/133 (21%) and seven patients were treated with cidofovir. Liver biopsies, performed in 76 patients revealed portal and lobular inflammation with none identifying a viral etiology. Eleven patients underwent liver transplantation, four were adenovirus positive, all of whom survived. There were four reported deaths.Conclusions: In this large data set of pediatric patients with severe acute hepatitis, the majority did not have a singular definitive etiology but did recover spontaneously. Continued community surveillance and close cooperation are critical toward understanding the etiology of such clusters in pediatrics.
- 19 May 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (2) , 177-182
Open AccessSevere hepatitis in pediatric patients: The Severe Hepatitis In Pediatric Patients (SHIPP) registry
Objectives: Clusters of severe acute hepatitis in children were reported worldwide beginning in October 2021. Although most children recovered, some progressed to liver failure leading to death or liver transplantation. Herein, we characterize the clinical characteristics, and outcomes of this group of children through an international collaborative effort.Methods: Participation was solicited via a global listserv to pediatric gastroenterologists worldwide. Patients 500 U/L, without chronic liver disease or acetaminophen ingestion were eligible. Data were submitted by individual sites into a Research Electronic Data Capture registry created in July 2022.Results: Two hundred and seven cases were collected, with a peak incidence of 28 in April 2022. The median age was 40 months, 52.7% were male, 63.3% were white, and 44% were Hispanic. At presentation, 80% reported gastrointestinal symptoms followed by fever (27.7%). The median duration of hospitalization was 5.5 days with 51 patients requiring intensive care. Adenovirus serum/whole blood DNA was detected in 28/133 (21%) and seven patients were treated with cidofovir. Liver biopsies, performed in 76 patients revealed portal and lobular inflammation with none identifying a viral etiology. Eleven patients underwent liver transplantation, four were adenovirus positive, all of whom survived. There were four reported deaths.Conclusions: In this large data set of pediatric patients with severe acute hepatitis, the majority did not have a singular definitive etiology but did recover spontaneously. Continued community surveillance and close cooperation are critical toward understanding the etiology of such clusters in pediatrics.
- 22 January 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 80 (4) , 549-558
Recent advances in the management of pediatric cholestatic liver diseases
Pediatric cholestatic liver diseases are rare conditions that can result from multiple specific underlying etiologies. Among the most common etiologies of pediatric cholestatic liver diseases are biliary atresia, Alagille syndrome (ALGS), and inherited disorders of bile acid transport. These diseases are characterized by episodic or chronic unremitting cholestasis. Due to the chronicity of these conditions, it is imperative to optimize medical management to improve patient quality of life, provide nutritional support, and reduce bile acid toxicity in efforts to slow disease progression. Cholestatic liver diseases remain the leading cause of pediatric liver transplantation, as many underlying disease etiologies have no curative medical therapies. In the present review, we provide an update on the nutritional, medical, and surgical management of pediatric cholestatic liver diseases. As recent advances have occurred in the field with the addition of ileal bile acid transporter (IBAT) inhibitors, we also review the results from prospective clinical trials, including their strengths and limitations. While recent clinical trials have demonstrated improved pruritus using IBAT inhibitors in ALGS and progressive familial intrahepatic cholestasis, establishing medical therapies proven to slow disease progression remains an area of unmet need.
- 22 January 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 80 (4) , 549-558
Recent advances in the management of pediatric cholestatic liver diseases
Pediatric cholestatic liver diseases are rare conditions that can result from multiple specific underlying etiologies. Among the most common etiologies of pediatric cholestatic liver diseases are biliary atresia, Alagille syndrome (ALGS), and inherited disorders of bile acid transport. These diseases are characterized by episodic or chronic unremitting cholestasis. Due to the chronicity of these conditions, it is imperative to optimize medical management to improve patient quality of life, provide nutritional support, and reduce bile acid toxicity in efforts to slow disease progression. Cholestatic liver diseases remain the leading cause of pediatric liver transplantation, as many underlying disease etiologies have no curative medical therapies. In the present review, we provide an update on the nutritional, medical, and surgical management of pediatric cholestatic liver diseases. As recent advances have occurred in the field with the addition of ileal bile acid transporter (IBAT) inhibitors, we also review the results from prospective clinical trials, including their strengths and limitations. While recent clinical trials have demonstrated improved pruritus using IBAT inhibitors in ALGS and progressive familial intrahepatic cholestasis, establishing medical therapies proven to slow disease progression remains an area of unmet need.
- 19 January 2024
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (1) , e14671
Anti‐spike antibody durability after SARS‐CoV‐2 vaccination in adolescent solid organ transplant recipients
Background: Adolescent solid organ transplant recipients (aSOTRs) who received three doses of the COVID‐19 mRNA vaccine experience high seroconversion rates and antibody persistence for up to 3 months. Long‐term antibody durability beyond this timeframe following three doses of the SARS‐CoV‐2 mRNA vaccine remains unknown. We describe antibody responses 6 months following the third vaccine dose (D3) of the BNT162b2 mRNA vaccination among aSOTRs.Methods: Participants in a multi‐center, observational cohort who received the third dose of the vaccine were analyzed for antibodies to the SARS‐CoV‐2 spike protein receptor‐binding domain (Roche Elecsys anti‐SARS‐CoV‐2‐S positive: ≥0.8, maximum: >2500 U/mL). Samples were collected at 1‐, 3‐, and 6‐months post‐D3. Participants were surveyed at each timepoint and at 12‐months post‐D3.Results: All 34 participants had positive anti‐RBD antibody titers 6 months post‐D3. Variations in titers occurred between 3 and 6 months post‐D3, with 8/28 (29%) having decreased antibody levels at 6 months compared to 3 months and 2/28 (7%) reporting increased titers at 6 months. The remaining 18/28 (64%) had unchanged antibody titers compared to 3‐month post‐D3 levels. A total of 4/34 (12%) reported breakthrough infection within 6 months and 3/32 (9%) reported infection after 6–12 months following the third dose of the SARS‐CoV‐2 mRNA vaccine.Conclusions: The results suggest that antibody durability persists up to 6 months following three doses of the SARS‐CoV‐2 mRNA in aSOTRs. Demography and transplant characteristics did not differ for those who experienced antibody weaning. Breakthrough infections did occur, reflecting immune‐evasive nature of novel variants such as Omicron.
- 19 January 2024
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (1) , e14671
Anti‐spike antibody durability after SARS‐CoV‐2 vaccination in adolescent solid organ transplant recipients
Background: Adolescent solid organ transplant recipients (aSOTRs) who received three doses of the COVID‐19 mRNA vaccine experience high seroconversion rates and antibody persistence for up to 3 months. Long‐term antibody durability beyond this timeframe following three doses of the SARS‐CoV‐2 mRNA vaccine remains unknown. We describe antibody responses 6 months following the third vaccine dose (D3) of the BNT162b2 mRNA vaccination among aSOTRs.Methods: Participants in a multi‐center, observational cohort who received the third dose of the vaccine were analyzed for antibodies to the SARS‐CoV‐2 spike protein receptor‐binding domain (Roche Elecsys anti‐SARS‐CoV‐2‐S positive: ≥0.8, maximum: >2500 U/mL). Samples were collected at 1‐, 3‐, and 6‐months post‐D3. Participants were surveyed at each timepoint and at 12‐months post‐D3.Results: All 34 participants had positive anti‐RBD antibody titers 6 months post‐D3. Variations in titers occurred between 3 and 6 months post‐D3, with 8/28 (29%) having decreased antibody levels at 6 months compared to 3 months and 2/28 (7%) reporting increased titers at 6 months. The remaining 18/28 (64%) had unchanged antibody titers compared to 3‐month post‐D3 levels. A total of 4/34 (12%) reported breakthrough infection within 6 months and 3/32 (9%) reported infection after 6–12 months following the third dose of the SARS‐CoV‐2 mRNA vaccine.Conclusions: The results suggest that antibody durability persists up to 6 months following three doses of the SARS‐CoV‐2 mRNA in aSOTRs. Demography and transplant characteristics did not differ for those who experienced antibody weaning. Breakthrough infections did occur, reflecting immune‐evasive nature of novel variants such as Omicron.
- Open Access
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (10) , 2481-2483
Antibody response to three SARS-CoV-2 mRNA vaccines in adolescent solid organ transplant recipients
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (10) , 2481-2483
Open AccessAntibody response to three SARS-CoV-2 mRNA vaccines in adolescent solid organ transplant recipients
- Open Access
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (2) , 669-672
Antibody response to 2-dose SARS-CoV-2 mRNA vaccination in pediatric solid organ transplant recipients
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (2) , 669-672
Open AccessAntibody response to 2-dose SARS-CoV-2 mRNA vaccination in pediatric solid organ transplant recipients
- 22 October 2022
- Published by Wiley in Pediatric Transplantation
- Vol. 27 (1) , e14409
Feasibility of using a patient‐reported outcome measure into clinical practice following pediatric liver transplantation: The Starzl Network experience
Background: Patient‐reported outcome measures (PROMs) are not routinely used in clinical care by pediatric liver transplant (LT) teams. The Starzl Network for Excellence in Pediatric Transplantation (SNEPT) assessed feasibility of using a disease‐specific Quality of Life (QoL) questionnaire in the ambulatory setting at 10 SNEPT sites.Methods: A mixed methods feasibility project assessing administration processes, barriers, and user experiences with the Pediatric Liver Transplant Quality of Life (PeLTQL) tool. Iterative processes sought stakeholder feedback across four phases (Pilot, Extended Pilot, Development of a Mobile App PeLTQL version, and Pilot App use).Results: A total of 149 patient–parent dyads completed the PeLTQL during LT clinic follow‐up. Clinicians, parents, and patients evaluated and reported on feasibility of operationalization. Only two of 10 SNEPT sites continued PeLTQL administration after the initial two pilot phases. Reasons include limited clinical time and available personnel aggravated by the COVID‐19 pandemic. In response, a mobile application version of the PeLTQL was initiated. Providing PeLTQL responses electronically was “very easy” or “easy” as reported by 96% (22/23) parents.Conclusions: Administration of a PROM into post‐pediatric LT clinical care was feasible, but ongoing utilization stalled. Use of a mobile app towards facilitating completion of the PeLTQL outside of clinic hours may address the time and work‐flow barriers identified.
- 22 October 2022
- Published by Wiley in Pediatric Transplantation
- Vol. 27 (1) , e14409
Feasibility of using a patient‐reported outcome measure into clinical practice following pediatric liver transplantation: The Starzl Network experience
Background: Patient‐reported outcome measures (PROMs) are not routinely used in clinical care by pediatric liver transplant (LT) teams. The Starzl Network for Excellence in Pediatric Transplantation (SNEPT) assessed feasibility of using a disease‐specific Quality of Life (QoL) questionnaire in the ambulatory setting at 10 SNEPT sites.Methods: A mixed methods feasibility project assessing administration processes, barriers, and user experiences with the Pediatric Liver Transplant Quality of Life (PeLTQL) tool. Iterative processes sought stakeholder feedback across four phases (Pilot, Extended Pilot, Development of a Mobile App PeLTQL version, and Pilot App use).Results: A total of 149 patient–parent dyads completed the PeLTQL during LT clinic follow‐up. Clinicians, parents, and patients evaluated and reported on feasibility of operationalization. Only two of 10 SNEPT sites continued PeLTQL administration after the initial two pilot phases. Reasons include limited clinical time and available personnel aggravated by the COVID‐19 pandemic. In response, a mobile application version of the PeLTQL was initiated. Providing PeLTQL responses electronically was “very easy” or “easy” as reported by 96% (22/23) parents.Conclusions: Administration of a PROM into post‐pediatric LT clinical care was feasible, but ongoing utilization stalled. Use of a mobile app towards facilitating completion of the PeLTQL outside of clinic hours may address the time and work‐flow barriers identified.